Evidence map›Paper›PMID 33014336›Full record

ArticlePulmonary circulation

Clinical and imaging outcomes after intermediate- or high-risk pulmonary embolus.

Daniel Lachant, Christina Bach, Bennett Wilson, Vaseem Chengazi, Bruce Goldman, Neil Lachant, Anthony Pietropaoli, Scott Cameron, R James White

Open access · goldAbstract read
In one paragraph

Article in Pulmonary circulation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 14 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Daniel LachantDivision of Pulmonary and Critical Care Medicine, University of Rochester Medical Center, Rochester, NY, USA.ORCID https://orcid.org/0000-0003-3441-8264
Christina BachDivision of Pulmonary and Critical Care Medicine, University of Rochester Medical Center, Rochester, NY, USA.
Bennett WilsonDivision of Pathology, University of Rochester Medical Center, Rochester, NY, USA.
Vaseem ChengaziDivision of Radiology and Nuclear Medicine, University of Rochester Medical Center, Rochester, NY, USA.
Bruce GoldmanDivision of Pathology, University of Rochester Medical Center, Rochester, NY, USA.
Neil LachantDivision of Hematology at the Wilmont Cancer Center, University of Rochester Medical Center, Rochester, NY, USA.
Anthony PietropaoliDivision of Pulmonary and Critical Care Medicine, University of Rochester Medical Center, Rochester, NY, USA.
Scott CameronDivision of Cardiology, University of Rochester Medical Center, Rochester, NY, USA.ORCID https://orcid.org/0000-0002-9616-1540
R James WhiteDivision of Pulmonary and Critical Care Medicine, University of Rochester Medical Center, Rochester, NY, USA.ORCID https://orcid.org/0000-0003-1399-5206
University of Rochester Medical Center · US

Funding

Platelet ERK5 regulates myocardial infarct expansionK08HL128856 · NHLBI · UNIVERSITY OF ROCHESTER · PI CAMERON, SCOTT JAMES · 2016 to 2020
$775k
NHLBI NIH HHS K08 HL128856
6 · The paper itself

Abstract

Long-term outcomes after acute pulmonary embolism vary from complete resolution to chronic thromboembolic pulmonary hypertension (CTEPH). Guidelines after acute pulmonary embolism are generally limited to anticoagulation duration. We assessed patients with estimated prognosis >1 year in our pulmonary hypertension clinic 2-4 months after treatment for intermediate- or high-risk acute pulmonary embolism. At follow-up, ventilation-perfusion scan and echocardiogram were offered. The aim of this study was to assess for recurrent symptomatic disease, residual imaging defects or right ventricular dysfunction, and functional disability after acute management of pulmonary embolism. After treatment for acute intermediate- or high-risk pulmonary embolism, 104 patients followed up in pulmonary hypertension clinic. Of those, 55% of patients had self-reported limitation in activity. No patients had symptomatic recurrence of pulmonary embolism. Forty-eight percent of patients had residual perfusion defects on perfusion imaging, while 91% of patients had either normal or only mildly enlarged right ventricles. We identified heart failure preserved ejection fraction, iron deficiency, and obstructive sleep apnea as significant contributors to breathlessness. Treatment of these conditions was associated with improvement. Surprisingly, we diagnosed CTEPH in nine patients; for some, chronic thrombus may already have been present at the time of index evaluation. Our findings suggest that follow-up in a dedicated pulmonary hypertension clinic 2-4 months after acute intermediate- or high-risk pulmonary embolism may add value to patient care. We identified treatable comorbidities that could be contributing to post-pulmonary embolism syndrome as well as CTEPH.

Indexed as

anticoagulantspulmonary embolismpulmonary hypertension

Identifiers

PMID33014336
PMCPMC7509735
OpenAlexW3088801923

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.